BDI visits US Ellison "Confirms key pipeline clinical trials"

[Asia Economy Reporter Hyunseok Yoo] VIDI announced on the 20th that it visited Allison Pharmaceuticals (Allison) in the United States to check the progress of clinical trials for major pipelines and the situation related to Nasdaq.

Among the four pipelines owned by Allison, the pancreatic cancer new drug treatment 'Glufosfamide' is currently undergoing Phase 3 clinical trials steadily. In addition to the FDA clinical trials, Allison plans to conduct additional Phase 3 trials in Europe and Asia in September. Through this, they aim to sell the drug in 2023 after receiving approval at the end of 2022.

The lung cancer and osteosarcoma treatment ILC (inhalation therapy) recently received approval for the Phase 2/3 clinical trial application submitted to the FDA by Allison. Full-scale clinical trials are expected to begin soon. Production of ILC drugs for clinical trials within this year is anticipated to be possible.

The brain cancer treatment 'DBD (Dibromodulcitol)' recently obtained a new substance patent in Europe by changing the molecular structure formula without fundamentally altering the characteristics of the existing drug. Allison plans to promote Phase 3 clinical trials based on this new drug substance in the first half of next year.

Also, Allison recently hired a Medical Officer, an essential personnel for Nasdaq listing. Although specific schedules cannot be disclosed due to regulations by the U.S. Securities and Exchange Commission (SEC), VIDI confirmed that Allison is actively considering listing on Nasdaq.

A VIDI official said, “Through this visit, we reviewed information that could not be obtained from previous non-face-to-face meetings, as well as Allison’s overall business and financial status, business and governance structure, reaffirming VIDI’s control as the largest shareholder. We directly confirmed the progress of clinical trials for major pipelines and the situation related to Nasdaq, which are of interest to domestic shareholders.”

He added, “During this visit, Allison requested active cooperation such as additional investment by VIDI, the largest shareholder, when proceeding with the Nasdaq listing in the future. VIDI will not only cooperate with Allison’s request but also actively consider additional equity investment going forward.”

This content was produced with the assistance of AI translation services.